

Clinical Governance Committee Report to Grampian NHS Board Committee Meeting on 22 November 2019

Purpose of Report

This report updates the Grampian NHS Board on key issues and corporate risk rating arising from the Clinical Governance Committee meeting on 22 November 2019.

Risk: The Clinical Governance Committee is the assurance source for the following strategic risk: ID 2507: Quality and Safety of Care: There is a risk that the focus on quality and safety of care across NHS Grampian and partner organisations could be compromised due to culture, service and financial pressures and/or a failure to monitor and implement improvements based on new evidence based guidance, evidence from quality audits, independent assessment, patient experience and recorded incidents. This risk remains categorised as high.

Recommendation

The Chair sought and received confirmation from all Committee Non-Executive members that they could assure the NHS Grampian Board that risk ID 2507 was being appropriately managed and controlled by the Executive.

The Board is asked to note the following key points:

- Clinical Quality & Safety Subgroup Quarterly Report:** The Committee receive a report each quarter which combines data from the weekly NHS Grampian Clinical Risk Meeting and information from the 2 Clinical Quality & Safety Subgroup meetings. The paper provides a cross system focus for learning, mitigation of clinical quality and safety of care risks and identification of areas for improvement. This report has developed well and there is evidence of reporting into other subgroups.
- Progress on Quality and Safety Risk Profile:** The Committee noted the progress of the quality and safety risk profile and the evidence of the risk being managed and reviewed. There has been a change in direction of risk management and risks being identified and managed at appropriate levels in the organisation. There are plans to appoint a corporate risk advisor.
- Clostridioides difficile infection (CDI) management:** The healthcare associated CDI incidence rates are below the national average in Quarter 2 (Apr-Jun 2019). The Infection Prevention and Control team have received feedback from Health Protection Scotland as having a very robust process in place for validating their CDI cases, which is reflected in the Boards improved CDI rates since the exception report was issued and HPS agreed that NHSG should continue this practice and share it across Scotland.
- Pharmacy Reporting:** The Committee received papers on the proposed future pharmacy and medication safety assurance reporting. There are plans that senior pharmacy staff member across each sector will review the risks identified within their sector governance report. This process will allow Grampian pharmacy risks to be described in the same way, risk and mitigation strategies to be updated and any new risks recorded in a systematic process.

Medication safety assurance reporting will focus on the Sector Clinical Risk Management Groups. These groups will report to the Clinical Quality & Safety Sub-group. The Area Drug and Therapeutics Committee (ADTC) will consider assurance across Grampian in terms of completeness of risk identification and sector management of those risks. There will be an annual report presented to the Clinical Governance Committee.

Ms Joyce Duncan
NHS Grampian Clinical Governance Committee, Chair

22 November 2019